Sponsors Should Discuss DSMB Trial Recommendations With FDA - Alpert
This article was originally published in The Gray Sheet
Executive Summary
Industry should consult FDA before discontinuing a trial on the recommendation of a data safety monitoring board (DSMB) for safety reasons, Office of Device Evaluation Director Susan Alpert, MD/PhD stated at a Jan. 13 Food and Drug Law Institute conference.